Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02679729
Recruitment Status : Completed
First Posted : February 10, 2016
Results First Posted : November 5, 2018
Last Update Posted : November 5, 2018
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Tracking Information
First Submitted Date  ICMJE February 3, 2016
First Posted Date  ICMJE February 10, 2016
Results First Submitted Date  ICMJE August 11, 2017
Results First Posted Date  ICMJE November 5, 2018
Last Update Posted Date November 5, 2018
Actual Study Start Date  ICMJE February 11, 2016
Actual Primary Completion Date October 24, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 16, 2018)
Safety and Tolerability of AZD5634 Following Inhaled Administration of Single-ascending Doses (SAD) (Part A) and Following Administration of Single Inhaled and IV Doses (Part B). [ Time Frame: Screening (serious adverse event, SAE), Day -1 (SAE), Spontaneous plus Predose, 3,12,24, and 48 h postdose (Days 1 to 3), Follow-up 7-10 days postdose, 2 months post final dose. ]
To assess the safety and tolerability of AZD5634 in terms of number of participants following inhaled administration of single-ascending doses (SAD) (Part A) and following administration of single inhaled and IV doses (Part B)
Original Primary Outcome Measures  ICMJE
 (submitted: February 5, 2016)
  • Frequencies of adverse events [ Time Frame: From screening to 2 months post final dose ]
    To assess the frequencies of adverse events
  • Percentages of adverse events [ Time Frame: From screening to 2 months post final dose ]
    To assess the percentages of adverse events
  • Supine heart rate [ Time Frame: From screening up to 10 days postdose ]
    To assess change from baseline in supine heart rate
  • Supine blood pressure [ Time Frame: From screening up to 10 days postdose ]
    To assess change from baseline in supine blood pressure
  • Supine pulse oximetry [ Time Frame: From screening to up to 10 days postdose ]
    To assess change from baseline in supine pulse oximetry
  • Supine respiratory rate [ Time Frame: From screening up to 10 days postdose ]
    To assess change from baseline in supine respiratory rate
  • Supine body temperature [ Time Frame: From screening up to 10 days postdose ]
    To assess change from baseline in supine body temperature
  • 12-lead electrocardiogram [ Time Frame: during study days 1 and 2 ]
    To assess 12-lead electrocardiogram
  • 12-lead electrocardiogram (cardiac telemetry) [ Time Frame: Part A: From day -1 to 24 hours postdose; Part B: From day -1 to 48 hours postdose ]
    To assess the cardiac telemetry by telemetry monitoring system
  • Safety electrocardiogram [ Time Frame: From screening up to 10 days postdose ]
    To assess safety electrocardiogram
  • Chemistry evaluations [ Time Frame: From screening to 2 months postdose ]
    To assess chemistry
  • Hematology evaluations [ Time Frame: From screening to 2 months postdose ]
    To assess hematology
  • Physical examination [ Time Frame: From screening up to 10 days postdose ]
    To assess subject through a physical examination
  • Spirometry [ Time Frame: From screening to 2 months postdose ]
    To assess spirometry
  • Urine collection [ Time Frame: From 12 hours predose to 48 hours postdose ]
    To assess fractional excretion of potassium and transtubular potassium gradient
  • Urinalysis evaluations [ Time Frame: From screening to 2 months postdose ]
    To assess urinalysis
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 16, 2018)
  • Observed Maximum Plasma Concentration, Taken Directly From the Individual Concentration-time Curve (Cmax)- For Part A and Part B [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic (PK) parameter Cmax of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and following single-dose IV or inhalation administration of AZD5634 in Part B. Note: Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
  • Area Under Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) for Part A and Part B [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter AUC of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and following single-dose IV or inhalation administration of AZD5634 in Part B. AUC was estimated by AUC(0-last) + Clast/λz where Clast was the last observed quantifiable concentration. AUCs were calculated using the linear trapezoidal method when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing. AUC0-t is expanded as area under the plasma concentration-time curve from time zero to time of last quantifiable concentration. Note:Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
  • Area Under the Plasma Concentration-curve From Time Zero to Time of Last Quantifiable Concentration [AUC(0-t)] for Part A and Part B [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter AUC(0-t) of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and following single-dose IV or inhalation administration of AZD5634 in Part B. Note: Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
  • Absolute Systemic Bioavailability After Inhalation (Part B Only) (Finhalation,Total) [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the Absolute systemic bioavailability after inhalation (%), calculated separately as 100*AUCinhalation*Doseiv/(AUCiv*Doseinhalation)
  • Renal Clearance (CLR), Estimated by Dividing Ae(0-last) by AUC0-t - For Part A and Part B [ Time Frame: -12-0, 0-6, 6-12, 12-24, 24-48 h (Days 1 to 3) ]
    To assess the pharmacokinetic parameter CLR of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and following single-dose IV or inhalation administration of AZD5634 in Part B. Note: Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
  • Cmax, Divided by the Dose Aministered (Cmax/Dose) - For Part A and Part B [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter Cmax/Dose of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and following single-dose IV or inhalation administration of AZD5634 in Part B. Note: Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
  • Terminal Half-life (t1/2λz), Estimated as (ln2)/λz - For Part A and Part B [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter t1/2λz of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and following single-dose IV or inhalation administration of AZD5634 in Part B. Note: Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
  • AUC0-t, Divided by the Dose Administered (AUC0-t/Dose) - For Part A and Part B [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter AUC0-t/Dose of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and following single-dose IV or inhalation administration of AZD5634 in Part B. Note: Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
  • AUC, Divided by the Dose Administered (AUC/Dose) - For Part A and Part B [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter AUC/Dose of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and following single-dose IV or inhalation administration of AZD5634 in Part B. Note: Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
  • Systemic Clearance for AZD5634 Estimated as Dose Divided by AUC (Part B IV Dosing Only) (CL) [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter CL of AZD5634 following single-dose IV administration of AZD5634 in Part B
  • Apparent Clearance for AZD5634 Estimated as Dose Divided by AUC (Part A and Part B Inhaled Dosing Only) (CL/F) [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter CL/F of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and following single-dose inhalation administration of AZD5634 in Part B. Note: Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
  • Mean Residence Time (MRT) - For Part A and Part B [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter MRT of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and following single-dose IV or inhalation administration of AZD5634 in Part B. Note: Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
  • Mean Absorption Time, Calculated as MRTinhaled - MRTIV (Part B Only) (MAT) [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter MAT of AZD5634 following single-dose IV or inhalation administration of AZD5634 in Part B
  • Volume of Distribution for AZD5634 at Steady State (IV Administration), Estimated by Dividing the MRT by the Systemic CL (Part B IV Dosing Only) (Vss) [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter Vss of AZD5634 following single-dose IV administration of AZD5634 in Part B
  • Volume of Distribution for AZD5634 at Terminal Phase (IV Administration), Estimated by Dividing the Systemic CL by λz (Part B IV Dosing Only) (Vz) [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter Vz of AZD5634 following single-dose IV administration of AZD5634 in Part B
  • Apparent Volume of Distribution for AZD5634 at Terminal Phase (Inhaled Administration), Estimated by Dividing the CL/F by λz (Part A and Part B Inhaled Dosing Only) (Vz/F) [ Time Frame: At predose, at 5, 15 and 30 min and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h postdose (Days 1 to 3) ]
    To assess the pharmacokinetic parameter Vz/F of AZD5634 following single-dose inhalation administration of AZD5634 in Part A and Part B. Note: Due to the participant and/or data exclusion described above, there are no PK data available for the 10 μg dose cohort and very limited data for the 27 μg dose cohort. Therefore, these 2 cohorts were not included in PK results interpretation and summary statistics.
Original Secondary Outcome Measures  ICMJE
 (submitted: February 5, 2016)
  • Observed maximum plasma concentration, taken directly from the individual concentration-time curve (Cmax) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Area under concentration-time curve from time zero extrapolated to infinity (AUC) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Area under the plasma concentration-curve from time zero to time of last quantifiable concentration [AUC(0-t)] [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Absolute Systemic Bioavailability After Inhalation (Part B Only) (Finhalation,Total) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Amount of AZD5634 excreted into the urine from time t1 to t2 [Ae(t1-t2)] [ Time Frame: From 12 hours predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Cumulative amount of AZD5634 excreted into the urine at the last sampling interval [Ae(0-last)] [ Time Frame: From 12 hours predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Fraction of dose excreted unchanged into the urine from time zero to the last measured time point for AZD5634 estimated by dividing Ae(0-last) by dose [fe(0-last)] [ Time Frame: From 12 hours predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Percentage of dose excreted unchanged into the urine from time zero to the last measured time point for AZD5634 estimated by dividing Ae(0-last) by dose [fe(0-last)%] [ Time Frame: From 12 hours predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Renal clearance (CLr), estimated by dividing Ae(0-last) by AUC0-t [ Time Frame: From 12 hours predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Cmax, divided by the dose administered (Cmax/Dose) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Time to reach maximum concentration, taken directly from the individual concentration-time curve (tmax) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Terminal half-life (t1/2λz), estimated as (ln2)/λz [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • AUC0-t, divided by the dose administered (AUC0-t/Dose) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • AUC, divided by the dose administered (AUC/Dose) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Systemic Clearance for AZD5634 Estimated as Dose Divided by AUC (Part B IV Dosing Only) (CL) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Apparent Clearance for AZD5634 Estimated as Dose Divided by AUC (Part A and Part B Inhaled Dosing Only) (CL/F) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Mean residence time (MRT) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Mean Absorption Time, Calculated as MRTinhaled - MRTIV (Part B Only) (MAT) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Volume of Distribution for AZD5634 at Steady State (IV Administration), Estimated by Dividing the MRT by the Systemic CL (Part B IV Dosing Only) (Vss) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Volume of Distribution for AZD5634 at Terminal Phase (IV Administration), Estimated by Dividing the Systemic CL by λz (Part B IV Dosing Only) (Vz) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Apparent Volume of Distribution for AZD5634 at Terminal Phase (Inhaled Administration), Estimated by Dividing the CL/F by λz (Part A and Part B Inhaled Dosing Only) (Vz/F) [ Time Frame: From predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
  • Fraction of dose excreted unchanged into the urine from time t1 to t2 [fe(t1-t2)] [ Time Frame: From 12 hours predose to 48 hours postdose ]
    To characterize the pharmacokinetics of AZD5634
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
Official Title  ICMJE A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Single-Ascending Inhaled Doses (Part A) and After Single Inhaled and Intravenous Doses (Part B) in Healthy Subjects
Brief Summary This is a Phase 1, first-in-human (FIH) single ascending dose study being conducted to better understand the safety, tolerability and pharmacokinetics of AZD5634 in healthy subjects
Detailed Description This study is a Phase I, FIH, randomized, single-blinded (study center staff remain blinded during the dosing phase of the study), placebo-controlled, single ascending dose, sequential dose group study in healthy male subjects and/or female subjects of non-childbearing potential at a single study center to assess AZD5634 following inhaled and intravenous dose administration
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Basic Science
Condition  ICMJE Cystic Fibrosis
Intervention  ICMJE
  • Drug: AZD5634 for inhalation
    Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
  • Drug: AZD5634 for infusion
    Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
  • Other: Placebo
    inactive substance
Study Arms  ICMJE
  • Experimental: Part A, Dose Level 1
    Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
    Interventions:
    • Drug: AZD5634 for inhalation
    • Other: Placebo
  • Experimental: Part A, Dose Level 2
    Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
    Interventions:
    • Drug: AZD5634 for inhalation
    • Other: Placebo
  • Experimental: Part A, Dose Level 3
    Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
    Interventions:
    • Drug: AZD5634 for inhalation
    • Other: Placebo
  • Experimental: Part A, Dose Level 4
    Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
    Interventions:
    • Drug: AZD5634 for inhalation
    • Other: Placebo
  • Experimental: Part A, Dose Level 5
    Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
    Interventions:
    • Drug: AZD5634 for inhalation
    • Other: Placebo
  • Experimental: Part A, Dose Level 6
    Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
    Interventions:
    • Drug: AZD5634 for inhalation
    • Other: Placebo
  • Experimental: Part A, Dose Level 7
    Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
    Interventions:
    • Drug: AZD5634 for inhalation
    • Other: Placebo
  • Experimental: Part B, Dose Level 1
    Subjects will receive a single dose of IV AZD5634 and after a washout period of 14 days the same subjects will receive a single dose of inhaled AZD5634
    Intervention: Drug: AZD5634 for infusion
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 6, 2017)
63
Original Estimated Enrollment  ICMJE
 (submitted: February 5, 2016)
78
Actual Study Completion Date  ICMJE October 24, 2016
Actual Primary Completion Date October 24, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Provision of signed and dated, written informed consent prior to any study specific procedures.
  2. Healthy male and/or female subjects aged 18 - 50 years with suitable veins for cannulation or repeated venipuncture.
  3. Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at screening by fulfilling 1 of the following criteria:

    • Post-menopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone (FSH) levels in the post-menopausal range.
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation.
  4. Have a body mass index (BMI) between 18 and 30 kg/m2, inclusive, and weigh at least 50 kg and no more than 100 kg, inclusive.
  5. Have a FEV1 (Forced expiratory volume in 1 second in liters) ≥ 80% of the predicted value at screening.
  6. Provision of signed, written and dated informed consent for optional genetic/biomarker research.

Exclusion Criteria:

  1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  2. History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the administration of investigational medicinal product (IMP).
  4. Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the investigator.
  5. Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV).
  6. Abnormal vital signs, after 10 minutes supine rest, at screening and check-in, defined as any of the following:

    • Systolic blood pressure (SBP) < 90mmHg (millimeter of mercury) or ≥ 140 mmHg
    • Diastolic blood pressure (DBP) < 50mmHg or ≥ 90 mmHg
    • Heart Rate < 45 or > 85 beats per minute (bpm)
  7. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12-lead ECG, as considered by the investigator that may interfere with the interpretation of QTc (QT [ECG interval measured from the onset of the QRS complex to the end of the T wave] interval corrected for heart rate) interval changes, including abnormal ST-T-wave morphology, particularly in the protocol defined primary lead or left ventricular hypertrophy, at screening.
  8. PR (PQ [ECG interval measured from the onset of the P wave to the onset of the QRS complex]) interval prolongation (> 240 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third degree atrioventricular (AV) block, or AV dissociation, at screening.
  9. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms. Subjects with QRS (ECG interval measured from the onset of the QRS complex to the J point) > 110 ms but < 115 ms are acceptable if there is no evidence of, for example, ventricular hypertrophy or pre-excitation, at screening.
  10. Serum/plasma potassium levels are outside the normal range and lower than 3.5 to 5.1 mEq/L (milliequivalents per liter) at screening and prior to dosing.
  11. Has active lung disease/asthma that requires treatment.
  12. Known or suspected history of drug abuse, as judged by the investigator.
  13. Current smokers or those who have smoked or used nicotine products within the previous 3 months.
  14. History of alcohol abuse or excessive intake of alcohol, as judged by the investigator.
  15. Positive screen for drugs of abuse, cotinine (nicotine), or alcohol at screening or admission to the unit.
  16. History of severe allergy/hypersensitivity or ongoing clinically significant allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD5634.
  17. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea, chocolate), as judged by the investigator.
  18. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the administration of IMP.
  19. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the administration of IMP or longer if the medication has a long half-life.
  20. Plasma donation within 1 month of screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening.
  21. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the administration of IMP in this study. The period of exclusion is 3 months after the final dose from a previous study.

    Note: Subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.

  22. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  23. Involvement of any Astra Zeneca, PAREXEL or study site employee or their close relatives.
  24. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
  25. Subjects who are vegans or have medical dietary restrictions.
  26. Subjects who cannot communicate reliably with the investigator.

    In addition, any of the following is regarded as a criterion for exclusion from the genetic research:

  27. Previous bone marrow transplant.
  28. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02679729
Other Study ID Numbers  ICMJE D6600C00001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party AstraZeneca
Study Sponsor  ICMJE AstraZeneca
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Ronald Goldwater, MDCM, M.Sc, CPI PAREXEL Early Phase Clinical Unit Baltimore
PRS Account AstraZeneca
Verification Date March 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP